Skip to main content
. Author manuscript; available in PMC: 2023 Jan 1.
Published in final edited form as: Cancer J. 2022 May-Jun;28(3):208–223. doi: 10.1097/PPO.0000000000000591

Figure 7.

Figure 7

Cochrane meta-analysis validates the Salpeter et al., meta-analyses (Fig. 6) showing similar reductions in all-cause mortality and coronary heart disease in women initiating HRT <60 years old and/or <10 years-since-menopause relative to placebo (26). Nineteen randomized controlled trials of 40,410 women comparing hormone replacement therapy of estrogen with or without progestogen with placebo. CI = confidence interval